207 related articles for article (PubMed ID: 35186442)
1. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.
Leclercq G; Servera LA; Danilin S; Challier J; Steinhoff N; Bossen C; Odermatt A; Nicolini V; Umaña P; Klein C; Bacac M; Giusti AM; Schneider A; Haegel H
Oncoimmunology; 2022; 11(1):2039432. PubMed ID: 35186442
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Leclercq-Cohen G; Steinhoff N; Albertí Servera L; Nassiri S; Danilin S; Piccione E; Yángüez E; Hüsser T; Herter S; Schmeing S; Gerber P; Schwalie P; Sam J; Briner S; Jenni S; Bianchi R; Biehl M; Cremasco F; Apostolopoulou K; Haegel H; Klein C; Umaña P; Bacac M
Clin Cancer Res; 2023 Nov; 29(21):4449-4463. PubMed ID: 37379429
[TBL] [Abstract][Full Text] [Related]
3. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
4. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
5. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
6. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.
Leclercq G; Steinhoff N; Haegel H; De Marco D; Bacac M; Klein C
Oncoimmunology; 2022; 11(1):2083479. PubMed ID: 35694193
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque.
Kamperschroer C; Guffroy M; Shen A; Dokmanovich M; Stubbs M; O'Donnell LM
J Immunother; 2024 Jun; 47(5):160-171. PubMed ID: 38562119
[TBL] [Abstract][Full Text] [Related]
8. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
[TBL] [Abstract][Full Text] [Related]
9. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
10. Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS).
Leclercq-Cohen G; Bacac M; Klein C
Expert Opin Biol Ther; 2023 Mar; 23(3):223-225. PubMed ID: 36629122
[No Abstract] [Full Text] [Related]
11. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
[TBL] [Abstract][Full Text] [Related]
12. Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Stewart MD; McCall B; Pasquini M; Yang AS; Britten CD; Chuk M; De Claro RA; George B; Gormley N; Horowitz MM; Kowack E; McCoy C; Morrow PK; Okoye E; Ricafort R; Rossi J; Sharon E; Theoret M; Vegni F; Yu T; Allen J
Cytotherapy; 2022 Jul; 24(7):742-749. PubMed ID: 35219582
[TBL] [Abstract][Full Text] [Related]
13. Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells.
Iwata Y; Narushima Y; Harada A; Mishima M
Toxicol Appl Pharmacol; 2022 Apr; 441():115986. PubMed ID: 35304238
[TBL] [Abstract][Full Text] [Related]
14. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
Li J; Piskol R; Ybarra R; Chen YJ; Li J; Slaga D; Hristopoulos M; Clark R; Modrusan Z; Totpal K; Junttila MR; Junttila TT
Sci Transl Med; 2019 Sep; 11(508):. PubMed ID: 31484792
[TBL] [Abstract][Full Text] [Related]
15. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
Jiang X; Chen X; Jaiprasart P; Carpenter TJ; Zhou R; Wang W
Eur J Pharm Sci; 2020 Apr; 146():105260. PubMed ID: 32058058
[TBL] [Abstract][Full Text] [Related]
16. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.
Shah D; Soper B; Shopland L
Front Immunol; 2023; 14():1190379. PubMed ID: 37304291
[TBL] [Abstract][Full Text] [Related]
17. Druggable Targets in Cytokine Release Syndromes.
Luri-Rey C; Eguren-Santamaria I; Matos I; Berraondo P; Melero I
Clin Cancer Res; 2023 Nov; 29(21):4320-4322. PubMed ID: 37656058
[TBL] [Abstract][Full Text] [Related]
18. Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model.
Martin GH; Gonon A; Martin-Jeantet P; Renart-Depontieu F; Biesova Z; Cifuentes A; Mukherjee A; Thisted T; Doerner A; Campbell DO; Bourré L; van der Horst EH; Rezza A; Thiam K
Front Immunol; 2024; 15():1357716. PubMed ID: 38384461
[TBL] [Abstract][Full Text] [Related]
19. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.
Kale SD; Mehrkens BN; Stegman MM; Kastelberg B; Carnes H; McNeill RJ; Rizzo A; Karyala SV; Coutermarsh-Ott S; Fretz JA; Sun Y; Koff JL; Rajagopalan G
Front Immunol; 2020; 11():1311. PubMed ID: 32676080
[TBL] [Abstract][Full Text] [Related]
20. Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.
Kroll KT; Mata MM; Homan KA; Micallef V; Carpy A; Hiratsuka K; Morizane R; Moisan A; Gubler M; Walz AC; Marrer-Berger E; Lewis JA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305322120. PubMed ID: 37603766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
